Immunovia Second Quarter 2025 Earnings: Misses Expectations

Immunovia (STO:IMMNOV) Second Quarter 2025 Results

Key Financial Results

• Net loss: kr41.1m (loss widened by 60% from 2Q 2024).
• kr0.14 loss per share.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Immunovia Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 90%. Earnings per share (EPS) also missed analyst estimates by 56%.

Looking ahead, revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in Sweden.

Performance of the Swedish Medical Equipment industry.

The company's shares are down 11% from a week ago.

Risk Analysis

We should say that we've discovered 5 warning signs for Immunovia (3 shouldn't be ignored!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.